Primary Renal Synovial Sarcoma and Clinical and Pathological Findings: a Systematic Review

Curr Urol Rep. 2021 Mar 11;22(4):25. doi: 10.1007/s11934-021-01038-w.


Purpose of review: To update epidemiological, diagnostic, and therapeutic information on primary synovial sarcoma of the kidney.

Recent findings: A total of 96 studies were analyzed; age at presentation was 38.6±14.2 years, predominant location of tumor was right kidney; frequent reported symptoms at diagnosis were hematuria and pain. For definitive diagnosis, cytogenetic technique was used. Detected oncogene was available in 37.8% cases with fusion of SS18-SSX in most patients. Surgery is treatment of choice, with adjuvant chemotherapy; most frequently ifosfamide-based associated with doxorubicin or epirubicin. Overall median survival was 34 months. Mortality was 29% of the cases which reported death and the recurrence rate was 39.8%. Risk of death was increased in patients with metastases at diagnosis Primary RSS occurs more often in young men. RSS often presents with symptoms and in an advanced stage. Surgical treatment is the most commonly used and chemotherapy for advanced or recurrent treatment.

Keywords: Kidney; Primary renal synovial sarcoma; Renal sarcoma; Renal tumor.

Publication types

  • Systematic Review

MeSH terms

  • Hematuria / etiology
  • Humans
  • Kidney Neoplasms / diagnosis*
  • Kidney Neoplasms / epidemiology
  • Kidney Neoplasms / pathology
  • Kidney Neoplasms / therapy*
  • Neoplasm Recurrence, Local* / pathology
  • Oncogene Proteins, Fusion / genetics
  • Pain / etiology
  • Sarcoma, Synovial / diagnosis*
  • Sarcoma, Synovial / epidemiology
  • Sarcoma, Synovial / secondary
  • Sarcoma, Synovial / therapy*
  • Survival Rate


  • Oncogene Proteins, Fusion
  • SYT-SSX fusion protein